# Proteomic and Antibody Production and Characterization

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2022 · $6,991,846

## Abstract

The National Cancer Institute (NCI)’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) comprises of an Antibody Program that comprehensively characterizes affinity reagents for cancer research via its Antibody Characterization Laboratory (ACL) located at the Frederick National Laboratory for Cancer Research (FNLCR) in Frederick, MD.  Within the ACL, a Proteomic Characterization Laboratory (PCL) pilot is to be established for comprehensive Mass Spectrometry (MS)-based proteomic characterization (global- and phospho-proteomes) and targeted (fit-for-purpose) assays.

## Key facts

- **NIH application ID:** 10687911
- **Project number:** 75N91019D00024-P00003-759102000029-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** ETHAN DMITROVSKY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $6,991,846
- **Award type:** —
- **Project period:** 2020-09-25 → 2025-09-24

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10687911

## Citation

> US National Institutes of Health, RePORTER application 10687911, Proteomic and Antibody Production and Characterization (75N91019D00024-P00003-759102000029-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10687911. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*